Biotechnology stocks are thriving right now. Over the past few months, the Health Care Select Sector SPDR ETF (XLV) has gained a vigorous 13% in value and the S&P Biotech ETF (XBI) has is also up double digits from the start of the year. It has been a pleasant year to be an investor in the sector, and as we move toward the last quarter of the year, many companies are looking at possible catalysts that could make it even more lucrative. When most investors think biotech, perhaps Big Pharma comes to mind, which already have treatments on the market and strong cash flows. But, we mustn’t forget some of these smaller names in this investment category that may have the ability to pack as big of a punch as their larger peers. After all, the biggest companies in the game at one time were much smaller. Smaller biotechs can offer underappreciated therapies that could thrive, when the right circumstances are encountered. The following companies’ share prices are small enough to possibly generate the extraordinary gains the industry is known for. Here’s what you should know about their possible catalysts on the horizon.Click Here For 3 Biotechs That May Have Favorable Catalysts On The Horizon